BioWorld - Sunday, January 11, 2026

Articles Tagged with ''Alzheimer’s disease''

Cassava phase III with simufilam fails in Alzheimer’s

Nov. 25, 2024
By Randy Osborne
The Alzheimer’s disease (AD) space took another blow along with the shares of Cassava Sciences Inc. (NASDAQ:SAVA), which plummeted by 83.8%, or $22.19, to end Nov. 25 at $4.30 after the firm unveiled top-line data from the phase III Rethink-Alz study with simufilam. The study tested simufilam in mild to moderate AD, where results fell short of each of the prespecified co-primary, secondary and exploratory biomarker endpoints.
Read More

Sage shuts down Huntington’s program after phase II failure

Nov. 20, 2024
By Lee Landenberger
The bad news keeps piling up for Sage Therapeutics Inc. Having absorbed other study stumbles in the past few months, the company now has halted development of dalzanemdor in treating Huntington’s disease after top-line phase II data showed it missed a statistically significant difference compared to placebo on the primary endpoint.
Read More

Eisai wins on appeal: CHMP recommends Leqembi for Alzheimer’s

Nov. 15, 2024
By Nuala Moran
The EMA has changed its mind about an earlier decision that the risks of Leqembi (lecanemab) outweigh the benefits and is now recommending the Alzheimer’s disease drug is approved for a subgroup of patients. That follows an appeal by Eisai Co. Ltd. and a re-examination of the data, after details relating to 274 patients with two copies of the ApoE4 gene were removed from the file.
Read More
X/Y chromosomes
Healing the health divide

The science of gender-based medicine: many reasons, many manifestations

Nov. 14, 2024
By Anette Breindl
At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias extended to both diseases and their causes – women’s health covered the breasts and reproductive system, and its causes were hormonal. Both concepts are far too narrow.
Read More
Group of multigenerational, multiracial women

Healing a health divide (that’s long overdue)

Nov. 14, 2024
By Lynn Yoffee
It’s difficult to fathom that the health of half the world’s population is underserved. But it’s a hard truth. There are many conditions that disproportionately impact women. Other conditions and diseases affect women in different ways than men. Decades of research excluding women from clinical trials and investment decisions in male-dominated board rooms have ignored these facts. Though an increasing number of women are now managing investments and driving the research, it’s all still woefully behind. In BioWorld’s new report, Healing the health divide, we’ve highlighted the disparities.
Read More